• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

    4/2/24 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email

    HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William ("Bill") A. Hudson, Jr., to the Company's Military & Government Advisory Board ("Advisory Board"). Nexalin's Advisory Board provides strategic advice and counsel to support the Company's advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies.

    Mr. Hudson is a partner in Tully Rinckey PLLC's Washington, D.C. office where he focuses his practice on military, security clearance, and federal employment law. Prior to joining the firm, Mr. Hudson was the president and CEO of Hudson Consulting, a firm focused on providing counsel to private industry in forming effective partnerships with governmental and non-governmental agencies and businesses and crafting innovative outreach strategies for the successful advancement of legislation and policy initiatives.

    Mr. Hudson served as the Acting General Counsel to the Department of Veterans Affairs (VA) from November 10, 2019, to January 20, 2021. As the Chief Legal Officer of the Department and Legal Advisor to the Secretary of Veterans Affairs, he oversaw and coordinated the work of the Office of the General Counsel (OGC) Central Office Law Groups, OGC's District Chief Counsel Offices, and OGC's National Practice Groups, which provide legal services in areas encompassing all of VA's Veterans' programs, personnel, torts, and general law subject matters. Prior to joining VA, Mr. Hudson served the Department of Defense (DoD) as Senior Counsel and Director, Congressional Investigations, Office of General Counsel. He previously served twice at DoD in the Office of General Counsel as Acting Deputy General Counsel (Legislation). Mr. Hudson is a recipient of the Department of Veterans Affairs Exceptional Service Award and a five-time recipient of the Secretary of Defense's Award for Exceptional Civilian Service.

    Mr. Hudson retired from the United States Army in 2010 as a Colonel with over 27 years of active service. He has a Master of Science in National Security Strategy from the National War College; a Master of Laws from the Judge Advocate General's Legal Center and School; a Juris Doctor from the University of South Carolina School of Law; and a Bachelor of Arts from The Citadel, The Military College of South Carolina. He is also a graduate from the U.S. Army Command and General Staff College.

    Mark White, CEO of Nexalin Technology stated, "We are honored to welcome Col. Bill Hudson to the Military & Government Advisory Board. Having held senior roles within the Department of Veterans Affairs and Department of Defense, Bill brings spectacular credentials and experience in navigating these complex agencies. He also has extensive experience in forming public-private partnerships, as well as deep relationships at all levels of government, which should be invaluable as we pursue collaborations with various government agencies. We look forward to leveraging his unique skill set to bring our new and drug-free therapy to active military personnel, veterans and others suffering from the devastating effects of PTSD, TBI (traumatic brain injury), anxiety, depression, insomnia, and other targeted indications."

    Mr. Hudson stated, "I am honored to support Nexalin in its mission to provide effective, drug-free treatment alternatives to patients with various mental health conditions that are often debilitating. I particularly look forward to helping advance the commercialization of the technology in order to improve healthcare outcomes for America's veterans who have honorably served our nation and deserve the best treatments available. Given the growing body of clinical evidence supporting the efficacy and potential of Nexalin's new advanced 15 mA waveform, I truly believe this technology holds enormous promise and I look forward to leveraging my expertise as well as my network to bring new hope to these patients."

    About Nexalin Technology, Inc.

    Nexalin designs and develops innovative and unique neurostimulation products to combat the ongoing global mental health epidemic. Nexilin's non-invasive products are undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp (mA) neurostimulation device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression.  Additional information about the Company is available at: https://nexalin.com/.

    FORWARD-LOOKING STATEMENTS

    This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact:

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: [email protected]

    Dave Gentry, CEO

    RedChip Companies Inc.

    407-491-4498

    [email protected]





    Primary Logo

    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by President and CEO White Mark

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:34:13 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Owens David

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:33:38 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

      HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company'

      2/26/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

      HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, ensuring Nexalin's commitment to innovation, safety, and excellence as the Company prepares to pursue global regulatory clearances and future FDA Breakthrough Device designations for its

      10/14/24 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Financials

    Live finance-specific insights

    See more
    • LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T

      11/1/24 9:00:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th

      7/26/24 9:55:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

      HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company's growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured interna

      5/28/25 10:00:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

      HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) --  Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. Maxim Group LLC acted as sole book-running manager for the offering. The public offering was made pursuant to an effective shelf registration statement on Form S-3

      5/6/25 2:40:23 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nexalin Technology Inc.

      10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

      5/13/25 3:31:04 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 12:39:21 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Nexalin Technology Inc.

      424B4 - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 11:44:26 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/5/25 3:17:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/4/25 5:05:25 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care